Pasotuxizumab, a Bite <sup>®</sup> Immune Therapy for Castration-Resistant Prostate Cancer: Phase I, Dose-Escalation Study Findings
-
- Horst-Dieter Hummel
- Translational Oncology/Early Clinical Trial Unit (ECTU), Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Oberdürrbacherstr. 6, 97080Würzburg, Germany
-
- Peter Kufer
- Research and Development, Amgen Research Munich GmbH, Staffelseestr. 2, 81477, Munich, Germany
-
- Carsten Grüllich
- Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Medical Center, Heidelberg, Germany; & Department of Oncology & Hematology, University Hospital Dresden, Haus 27, Fetscherstr. 74, 01307Dresden, Germany
-
- Ruth Seggewiss-Bernhardt
- Translational Oncology/Early Clinical Trial Unit (ECTU), Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Oberdürrbacherstr. 6, 97080Würzburg, Germany
-
- Barbara Deschler-Baier
- Translational Oncology, Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Josef-Schneider-Str. 6, 97080Würzburg, Germany
-
- Manik Chatterjee
- Translational Oncology/Early Clinical Trial Unit (ECTU), Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Oberdürrbacherstr. 6, 97080Würzburg, Germany
-
- Maria-Elisabeth Goebeler
- Translational Oncology/Early Clinical Trial Unit (ECTU), Medizinische Klinik II, University Hospital Würzburg, Oberdürrbacherstr. 6, 97080Würzburg, Germany
-
- Kurt Miller
- Department of Urology, Charité Universitätsmedizin Berlin, Charitéplatz. 1, 10117, Berlin, Germany
-
- Maria de Santis
- Department of Urology, Charité Universitätsmedizin Berlin, Charitéplatz. 1, 10117, Berlin, Germany
-
- Wolfgang Loidl
- Department of Urology, Ordensklinikum Linz GmbH Elisabethinen, Fadingerstr. 1, 4020, Linz, Austria
-
- Christian Dittrich
- Applied Cancer Research–Institution for Translational Research Vienna (ACR-ITR VIEnna) & Center for Oncology & Hematology, Kaiser Franz Josef-Spital, Bernardgasse 24/2, 1070, Vienna, Austria
-
- Andreas Buck
- Department of Nuclear Medicine, University Hospital Würzburg, Oberdürrbacherstr. 6, D-97080, Würzburg, Germany
-
- Constantin Lapa
- Department of Nuclear Medicine, University Hospital Würzburg, Oberdürrbacherstr. 6, D-97080, Würzburg, Germany
-
- Annette Thurner
- Department of Diagnostic & Interventional Radiology, University Hospital Würzburg, Oberdürrbacherstr. 6, 97080, Würzburg, Germany
-
- Sabine Wittemer-Rump
- Bayer AG, SBU Oncology, Pharmaceuticals, 13353, Berlin, Germany
-
- Gökben Koca
- Bayer AG, SBU Oncology, Pharmaceuticals, 13353, Berlin, Germany
-
- Oliver Boix
- Bayer AG, SBU Oncology, Pharmaceuticals, 13353, Berlin, Germany
-
- Wolf-Dietrich Döcke
- Bayer AG, SBU Oncology, Pharmaceuticals, 13353, Berlin, Germany
-
- Ricarda Finnern
- Bayer AG, SBU Oncology, Pharmaceuticals, 13353, Berlin, Germany
-
- Helena Kusi
- Bayer AG, SBU Oncology, Pharmaceuticals, 13353, Berlin, Germany
-
- Antoinette Ajavon-Hartmann
- Bayer AG, SBU Oncology, Pharmaceuticals, 13353, Berlin, Germany
-
- Sabine Stienen
- Research and Development, Amgen Research Munich GmbH, Staffelseestr. 2, 81477, Munich, Germany
-
- Cyrus Michael Sayehli
- Department of Nuclear Medicine, University Hospital Würzburg, Oberdürrbacherstr. 6, D-97080, Würzburg, Germany
-
- Bülent Polat
- Department of Radiation Oncology, University Hospital Würzburg, Josef-Schneider-Str. 11, 97080, Würzburg, Germany
-
- Ralf C Bargou
- Translational Oncology, Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Josef-Schneider-Str. 6, 97080Würzburg, Germany
収録刊行物
-
- Immunotherapy
-
Immunotherapy 13 (2), 125-141, 2020-11-10
Informa UK Limited
